Introduction
============

More recently, the progress of immune checkpoint inhibitors (ICIs), especially the programmed death-1 (PD-1) inhibitors, is changing the landscape of non-small cell lung cancer (NSCLC) treatment.[@b1-ott-11-3691],[@b2-ott-11-3691] To date, pembrolizumab and nivolumab have been approved by the US Food and Drug Administration (FDA) in treating melanoma and NSCLC patients.[@b3-ott-11-3691] PD-1 inhibitors, including nivolumab and pembrolizumab, restimulate T cells which have lost effector and proliferative function. Otherwise, without the PD-1 inhibition, immune cells are likely to lose proliferative function in the tumor microenvironment. PD-L1 is the ligand of PD-1, which was expressed in tumor cells. The tumor cells may escape the antitumor effect of T cells via overexpressing the PD-L1 molecules in the tumor microenvironment. Hence, using ICIs that block the cross talk of PD-L1 molecules and PD-1 molecules may inhibit tumor cells from evading the immunoreaction under this situation. Latest studies reveal that the efficacy of PD-1/PD-L1 inhibitors may correlate with sex and age;[@b4-ott-11-3691],[@b5-ott-11-3691] however, little is known whether it is associated with the status of smoking.

A number of studies have evaluated the correlation between smoking and efficacy of lung cancer treatment.[@b6-ott-11-3691] From a preclinical perspective, it was observed that cigarette smoking was associated with therapeutic response to chemotherapy and radiotherapy in cancer cells.[@b7-ott-11-3691] Interestingly, evidence revealed that smoking may induce the epithelial-to-mesenchymal transition in lung cancer cell lines.[@b8-ott-11-3691] In the clinical practice, several trials reported that smoking status affected the survival of NSCLC patients in the treatment with anti-PD-1 agents.[@b9-ott-11-3691] However, the lack of statistical power did not generate a meaningful difference. Whether smoking correlates with the effectiveness of PD-1/PD-L1 inhibitors was still unknown. Hence, we hypothesized that the efficacy of nivolumab and pembrolizumab is related to smoking status.

To the best of our knowledge, this is the first study that examined the association between smoking and PD-1/PD-L1 inhibitors' efficacy based on more than 1,000 patients. In this study, we conducted a meta-analysis of 1,981 patients to evaluate the clinical impact of smoking on the effectiveness of PD-1/PD-L1 treatment with a closer look at the survival of NSCLC patients.

Materials and methods
=====================

Study design and search strategy
--------------------------------

A search was performed in Google Scholar, PubMed, and Web of Science until February 2018. The process of search and trial selection was documented as shown in [Figure 1](#f1-ott-11-3691){ref-type="fig"}. The keywords included PD-1, PD-L1, non-small cell lung cancer, smoke, nivolumab, pembrolizumab, and clinical trials. Articles that were not published in English were excluded. We retrieved all studies of potential conflict of interest.

Selection criteria
------------------

Only trials that met the following five criteria could be included. 1) The trial should enroll NSCLC patients. 2) The intervention should be PD-1/PD-L1 inhibitors. 3) The control group should be other treatments. 4) The outcome of overall survival (OS) or progression-free survival (PFS) of subgroup analysis by smoking status should be reported. 5) The trial should be Phase III randomized controlled trials (RCTs). Non-English articles should be excluded. In addition, all the duplicated studies were excluded.

Data extraction and risk of bias assessment
-------------------------------------------

Two authors (Bingjia Li and Xiaoyu Huang) independently extracted the data. We checked the data very carefully. The following information was extracted from the trials: first author, year of publication, number of patients, PD-1/PD-L1 treatments and dosage, hazard ratio (HR) of PFS or OS, the smoking status. Three reviewers (Bingjia Li, Xiaoyu Huang, and Linlin Fu) independently assessed the risk of bias using the Cochrane Collaboration tool. Disagreements were solved by the first author (YC). The assessment of risk of bias is shown in [Figure 2](#f2-ott-11-3691){ref-type="fig"}.

Statistical analyses
--------------------

We used Stata 12 for Windows 8.1 to conduct statistical analyses, making forest plots and evaluation of publication bias. Review Manager 5.3 was used to examine the risk of bias. HR and confidence interval (CI) were used as effect sizes. If the *P*-value was \<0.05, the difference between two arms had a statistical significance. The heterogeneity would be low, moderate, and high, if the *I*[@b2-ott-11-3691] value was \<25%, 25%--50%, and \>50%, respectively.[@b22-ott-11-3691] Publication bias was examined by Egger's test.

Results
=======

Search results and patient characteristics
------------------------------------------

A total of 1,981 patients from four Phase III RCTs were included in this meta-analysis.[@b10-ott-11-3691]--[@b13-ott-11-3691] The procedure for trial selection is shown in [Figure 1](#f1-ott-11-3691){ref-type="fig"}. All the trials evaluated the efficacy of PD-1/PD-L1 inhibitors, including nivolumab (n = 826), pembrolizumab (n = 305), and atezolizumab (n = 850). All the patients had NSCLC. The characteristics of the RCTs are summarized in [Table 1](#t1-ott-11-3691){ref-type="table"}.

OS and PFS
----------

Three Phase III RCTs were included in OS analysis.[@b11-ott-11-3691]--[@b13-ott-11-3691] Likewise, PFS analysis was based on two Phase III RCTs.[@b10-ott-11-3691],[@b12-ott-11-3691] There was low or moderate heterogeneity (*I*[@b2-ott-11-3691] \< 50%) in OS and PFS analyses, respectively. Hence, fixed-effect models were used in both analyses. One study divided the smoking status into current smoking, former smoking, and never smoking,[@b10-ott-11-3691] and we combined the data of current smoking and former smoking for further analysis.

Our meta-analysis showed that PD-1/PD-L1 inhibitors significantly prolonged the OS in smoking patients (HR, 0.69; 95% CI, 0.60--0.78) versus chemotherapy ([Figure 3](#f3-ott-11-3691){ref-type="fig"}). However, among nonsmoking patients, no significant improved OS was observed (HR, 0.8; 95% CI, 0.54--1.06; *P* \> 0.05) compared with chemotherapy ([Figure 3](#f3-ott-11-3691){ref-type="fig"}). The PFS analysis indicated a significantly prolonged PFS in smoking patients treated with PD-1 inhibitors (HR, 0.55; 95% CI, 0.43--0.67; *P* = 0.027) versus chemotherapy ([Figure 4](#f4-ott-11-3691){ref-type="fig"}). Similarly, PFS in nonsmoking patients undergoing anti-PD-1 immunotherapy was not significantly longer (HR, 0.90; 95% CI, 0.11--7.59; *P* = 0.637) than the chemotherapy group.

Publication bias
----------------

No publication bias was observed in both the OS group (*P* = 0.865) and the PFS group (*P* = 0.635) by Egger's test.

Discussion
==========

To the best of our knowledge, this is the first attempt to collate and evaluate the efficacy of PD-1 inhibitors in smokers and nonsmokers. A few trials have depicted this phenomenon, but the lack of statistical power prevents a final conclusion.[@b9-ott-11-3691],[@b12-ott-11-3691] According to our meta-analysis, we found that smokers benefit more from PD-1 inhibitors in both OS and PFS than chemotherapy; however, among nonsmokers, no significantly prolonged survival was found as opposed to controls. This finding was consistent with a recent Phase II trial,[@b14-ott-11-3691] where smoking status was associated with better efficacy of nivolumab. Based on this trial, current/former smokers have a significantly better overall response rate (ORR) than nonsmokers (ORR, 29.1% versus 4.8%) among advanced or recurrent non-squamous NSCLC patients. Better median OS (17.4 versus 14.8 months) and median PFS (2.8 versus 1.4 months) was reported in smokers versus nonsmokers.

Smoking status is associated with the risk of lung cancer,[@b15-ott-11-3691] mortality of lung cancer,[@b16-ott-11-3691] and effectiveness of lung cancer treatment.[@b6-ott-11-3691] According to previous studies, our study offers new evidence in this field. However, the preclinical rationale for our finding still remains unknown. Bavarva et al[@b17-ott-11-3691] found that 20% of NSCLC tumors in smokers have mutations in at least one of the MUC4, MUC6 or MUC12 genes in contrast to only 6% in nonsmokers based on The Cancer Genome Atlas database. Another group demonstrated numbers of long noncoding RNAs (lncRNAs) which may underlie the molecular difference in smokers and nonsmokers.[@b18-ott-11-3691] However, there is still no evidence showing the reasons behind the difference in effectiveness in smokers/nonsmokers. From an immunological perspective, a group reported that smoking significantly regulated the maturation and function of dendritic cells.[@b19-ott-11-3691] Another group proved that smoking will impact the number of Treg cells.[@b20-ott-11-3691] Smoking may also alter the function of natural killer cells and inhibit the anti-tumor functions.[@b21-ott-11-3691] Despite a direct evidence of the association between smoking, efficacy of PD-1/PD-L1 inhibitor, and immune cells, these findings may partly explain our results. Dialogs among preclinical researchers and clinical scientists are needed to understand the biologic effect of smoking on cancer biology.

An advantage of our study was the ability to assess outcomes in smokers versus nonsmokers in a larger sample size as opposed to data often obtained from comparatively small group in RCTs. Nevertheless, this meta-analysis was faced with several shortcomings. A major concern was that the sample size of nonsmokers was still relatively small, although we had collected all the available data. Also, we cannot retrieve the data of toxicity of PD-1 inhibitors in smokers and nonsmokers. Hence, we cannot conduct analysis of adverse events by smoking status. Further meta-analysis of updated information is required.

Conclusion
==========

Our meta-analysis showed that PD-1/PD-L1 inhibitors were more efficacious in smoking NSCLC patients compared with chemotherapy. No improvement in survival of nonsmoking patients was observed following treatment with PD-1/PD-L1 inhibitors compared with chemotherapy. Difference in the efficacy of PD-1/PD-L1 treatment should be taken into consideration in the future guidelines and clinical practice.
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###### 

Characteristics of the studies included in the meta-analysis

  Study                               Phase      Cancer                                         Arm                     No. of patients for analysis   
  ----------------------------------- ---------- ---------------------------------------------- ----------------------- ------------------------------ -----------------------------------------------
  Reck et al[@b10-ott-11-3691]        III, RCT   Advanced NSCLC                                 Pembrolizumab 200 mg    149                            5
  ICC                                 132        19                                                                                                    
  Borghaei et al[@b11-ott-11-3691]    III, RCT   Advanced non-squamous NSCLC                    Nivolumab 3 mg/kg       231                            58
  Docetaxel                           227        60                                                                                                    
  Brahmer et al[@b12-ott-11-3691]     III, RCT   Advanced squamous NSCLC                        Nivolumab 3 mg/kg       121                            10[a](#tfn1-ott-11-3691){ref-type="table-fn"}
  Docetaxel                           129        7[a](#tfn1-ott-11-3691){ref-type="table-fn"}                                                          
  Rittmeyer et al[@b13-ott-11-3691]   III, RCT   Previous treated NSCLC                         Atezolizumab 1,200 mg   694                            156
  Docetaxel                                                                                                                                            

**Note:**

These subgroups were not included in the analysis because of the small sample size.

**Abbreviations:** ICC, investigator's choice of chemotherapy; NSCLC, non-small cell lung cancer; RCT, randomized controlled trial.
